cgp 39551 has been researched along with Anochlesia in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Maj, J; Rogóz, Z; Skuza, G | 1 |
Kretschmer, BD; Schmidt, WJ; Volz, L; Volz, TL; Zadow, B | 1 |
2 other study(ies) available for cgp 39551 and Anochlesia
Article | Year |
---|---|
Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity.
Topics: 2-Amino-5-phosphonovalerate; alpha-Methyltyrosine; Animals; Antiparkinson Agents; Antipsychotic Agents; Biogenic Monoamines; Catalepsy; Central Nervous System Agents; Clonidine; Levodopa; Male; Methyltyrosines; Motor Activity; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Reserpine; Tyrosine 3-Monooxygenase | 1993 |
The contribution of the different binding sites of the N-methyl-D-aspartate (NMDA) receptor to the expression of behavior.
Topics: 2-Amino-5-phosphonovalerate; Animals; Behavior, Animal; Binding Sites; Catalepsy; Cycloserine; Dizocilpine Maleate; Haloperidol; Male; Motor Activity; Rats; Rats, Inbred Strains; Receptors, N-Methyl-D-Aspartate | 1992 |